Introduction {#Sec1}
============

Prior to the introduction of effective post-transplantation antiviral prophylaxis, liver transplantation for hepatitis B virus (HBV)-related disease was usually followed by immediate HBV reinfection of the allograft, resulting in a fatal hepatitis B recurrence \[[@CR1]--[@CR3]\]. Recent studies have found that treatment with a combination of hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogues decreases the risk of hepatitis B recurrence, and achieves a higher rate of graft survival \[[@CR4]--[@CR8]\]. However, long-term administration of HBIg is associated with several unresolved issues, including limited availability and extremely high cost, so several protocols for treatment with low-dose HBIg in combination with nucleos(t)ide analogue have been reported \[[@CR9]--[@CR12]\]. Previously, we reported that treatment with high-dose HBIg in the early period post-transplantation followed by low-dose HBIg with nucleos(t)ide analogues offers reliable, cost-effective control of hepatitis B recurrence \[[@CR13]\]. However, even with such a simplified protocol, patients would still need to receive a drip infusion or intramuscular injection of hundreds to thousands of units of HBIg every 2--3 months.

Active immunization of post-orthotopic liver transplantation (OLT) recipients with HBV vaccine is a recently emerging approach. However, most studies report low response rates, even with double concentration of vaccines or prolonged vaccination regimens \[[@CR14], [@CR15]\]. Patients who had not been HBV carriers \[e.g., acute liver failure (ALF) patients following sexual transmission of HBV as an adult; or non-chronic HBV carrier patients who received hepatitis B core antibody (HBcAb)-positive livers\] are accepted as good candidates for vaccine administration \[[@CR15], [@CR16]\]. Vaccination in patients who have been HBV carriers or liver cirrhosis (LC) patients typically yields disappointing results \[[@CR14], [@CR15]\]. Understanding how different cohorts respond to HBV vaccination is critical to the design of safe, cost-saving, and custom-designed prophylaxis protocols.

It remains unclear to what extent cellular immune responses may contribute to protection from HBV reinfection. Since non-carrier patients respond well to the HBV vaccination, immune tolerance is expected to play a large role in this process. Yet only a few reports have mentioned T cell immune reaction after HBV-related OLT \[[@CR14]\].

In this report, we assessed a monthly, long-term vaccination protocol starting 1 year after OLT, to investigate those characteristics that could discriminate between the vaccine-responsive and non-responsive patients. In addition to anti-hepatitis B surface (anti-HBs) antibody titer due to a humoral immune response, CD4 T cell immune responses to hepatitis B surface antigen (HBsAg) were used to assess the cellular immune response to vaccination in immunocompetent patients.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

From October 1996 to June 2011, OLT was performed in 264 adults at Okayama University Hospital. Of these, ten patients had ALF due to acute HBV infection. Thirty-seven patients had end-stage LC due to chronic life-long HBV infection. Five-year survival rates were 88 and 87 % for HBV-related ALF patients and for HBV-related LC patients, respectively.

The HBV vaccine was administered to five ALF patients (ALF-OLT) and 22 LC patients (LC-OLT). The general characteristics of the patients included in this study are summarized in Table [1](#Tab1){ref-type="table"}. All of them received living donor liver transplantation (LDLT). The numerical data are expressed as median and interquartile range values, and categorical data are presented as positive counts or percentages in all tables.Table 1Patient characteristics*N*ALFLC522Recipient related factors Age at OLT29 (27--46)53 (47--56) Age at start of vaccine36 (30--51)56 (49--59) Sex (M)1 (20 %)19 (86 %) HBsAg at OLT0.7 (0--1)2000 (100--2000) HBV DNA at OLT (≥3.7)0 (0 %)8 (36 %) MELD at OLT21 \[[@CR19]--[@CR21]\]15 \[[@CR9]--[@CR18]\] HCC at OLT (+)0 (0 %)15 (68 %)Donor related factors Age at OLT32 (27--44)46 (31--49) Sex (M)4 (80 %)9 (40 %) ABO (identical)4 (80 %)12 (54 %) Blood relation (no)0 (0 %)8 (36 %) Anti-HBs antibody (\>100)1 (20 %)9 (40 %) Anti-HBc antibody (+)1 (20 %)11 (50 %) Anti-HBc(+)/anti-HBs(+)1 (20 %)10 (45 %) Anti-HBc(+)/anti-HBs(−)0 (0 %)1 (4 %) Anti-HBc(−)/anti-HBs(+)0 (0 %)0 (0 %)*ALF* acute liver failure, *LC* liver cirrhosis, *OLT* orthotopic liver transplantation, *MELD* Model for End-stage Liver Disease, *HCC* hepatocellular carcinoma

For analysis of the HBV-specific cellular immune response (Table [2](#Tab2){ref-type="table"}), the study enrolled all five ALF-OLT patients, along with 15 of the 22 LC-OLT patients. Additionally, 11 healthy volunteers who had received the HBV vaccine and developed a successful anti-HBs antibody response (termed 'Healthy vaccine'), ten patients with chronic hepatitis B (termed 'Chronic hepatitis'), and five patients who recovered from acute hepatitis B (termed 'Self-limited') were enrolled as controls. The five patients who recovered from acute hepatitis B had a history of acute hepatitis B diagnosed with high-titer IgM-HBc antibody response, and presented as HBsAg negative, anti-HBs antibody positive, anti-HBc antibody positive at the time of the study. The chronic hepatitis B patients were followed for several years at our hospital and all were HBsAg positive with a median HBV-DNA titer of 2.5 (interquartile range 2.1--4.2) logcopies/mL. The healthy volunteers had no HBsAg and anti-HBc antibodies, and the median anti-HBs antibody level was 240 (interquartile range 100--797) mIU/mL.Table 2Characteristics of the cases for HBV antigen-specific T cell response*N*Healthy vaccineChronic hepatitisSelf-limitedALF-OLTLC-OLT-goodLC-OLT-poor11105487Age29 (28--31)53 (42.5--61)67 (58.5--77)41.5 (37.2--47.2)60 (53--62)55 (40--58)Sex \[M (%)\]10 (91)7 (70)2 (40)0 (0)8 (100)7 (100)HBs Ag (+)010 \[titer 2000 (1893--2000)\]0000HBs Ab (IU/l) (\>100/≤100)8/30/102/32/24/41/6LC-OLT-poor patients received HBIG within 3 monthsAge and HBsAg were shown as median (interquartile range)*ALF-OLT* acute liver failure patients who received OLT, *LC-OLT-good* liver cirhosis patients who received OLT and had a good vaccine response, *LC-OLT-poor* liver cirrhosis patients who received OLT and had a poor vaccine response

Informed consent was obtained from each patient included in the study, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in the approval by the Ethics Committee at the Okayama University Hospital.

Antiviral prophylaxis {#Sec4}
---------------------

Our HBV prophylaxis protocol was as follows. We administered HBIg at 200 IU/kg intraoperatively. Recipients were administered another 2000 IU/week HBIg for an additional 1 week post-operatively. HBIg (2000 IU) was administered thereafter only when anti-HBs antibody titers fell below 100 mIU/mL. After 6 months, HBIg was administered only to maintain anti-HBs antibody titers at \>10 mIU/mL. We measured levels of HBsAg and anti-HBs antibody and/or HBV-DNA every month for 6 months after LDLT, and every 2--3 months thereafter. Three of the ALF-OLT patients were anti-HBs antibody positive at the time of OLT, these patients were not administered nucleos(t)ide analogues. The remaining two ALF-OLT patients, and all of the LC patients were given nucleos(t)ide analogues. The two ALF-OLT patients were given lamivudine (LAM), and of the 22 LC-OLT patients, 14 received LAM, six were given LAM + adefovir dipivoxyl (ADV), and two received entecavir (ETV). Administration of nucleos(t)ide analogues was started a minimum of 1 month pre-operatively, when possible.

Post-OLT re-activation of HBV was defined as continuous positivity for serum HBsAg and/or serum HBV-DNA.

HBV vaccine protocol {#Sec5}
--------------------

HBV vaccine administration was initiated at least 1 year after OLT, and when patients showed no active infection or rejection episode in the preceding month. The vaccine consisted of recombinant purified HBsAg (Bimmugen; Kaketsuken, Kumamoto, Japan). Ten micrograms were administered every 1--2 months. Based on the effect of the vaccine, patients were classified as "good responders; LC-OLT good" or "poor responders; LC-OLT poor". Patients who showed anti-HBs antibody titers above 100 mIU/mL without HBIg for a minimum of 6 months were defined as good responders, since all of these patients did not need HBIg administration for an additional 2 years (median) of follow-up. All other patients were defined as poor responders. Patients who showed a good response within 36 months were given additional vaccinations when their anti-HBs antibody titer decreased, whereas vaccination was stopped in patients who showed no good response after 36 months.

Immune suppression {#Sec6}
------------------

Patients were treated using a standard immunosuppressive regimen (tacrolimus or cyclosporine A with steroids and/or mycophenolate mofetil). One patient was free from calcineurin inhibitors at the time of vaccine administration.

Routine laboratory tests and serum HBV-DNA assay {#Sec7}
------------------------------------------------

Hepatitis B surface antigen, anti-HBs antibody, hepatitis Be antigen (HBeAg), and anti-HBe antibody (HBeAb) levels were measured routinely using a commercially available chemiluminescent enzyme immunoassay system (Lumipulse System; Fujirebio, Tokyo, Japan). HBV-DNA levels were measured using a transcription-mediated amplification assay (TMA) (SRL, Tokyo, Japan), a polymerase chain reaction (PCR) assay (Amplicor HBV Monitor assay; Roche Diagnostics, Tokyo, Japan), or a real-time PCR assay (COBAS TaqMan HBV Test; Roche Diagnostics).

HBV recombinant proteins for cellular immune response analysis {#Sec8}
--------------------------------------------------------------

Hepatitis B virus recombinant protein HBsAg was purchased from Advanced ImmunoChemical, Inc. (Long Beach, CA). Recombinant protein hepatitis B core antigen (HBcAg) was purchased from the Institute of Immunology (Tokyo, Japan). These proteins were used as stimulating antigens at 1 μg/mL for the enzyme-linked immunospot (ELISPOT) assay.

CD14-positive monocyte isolation and myeloid DC generation {#Sec9}
----------------------------------------------------------

Mononuclear cells were separated from peripheral blood by centrifugation on the Ficoll-Hypaque density gradient (Amersham Pharmacia, Uppsala, Sweden), as previously described. CD14-positive monocytes were purified using microbeads (Miltenyi Biotec, Auburn, CA) in accordance with the protocols of the manufacturer. Subsequently, CD4-positive T cells (T4) were positively sorted in the same way. T4 cells were frozen immediately. CD14-positive cells were cultured at 1 × 10^6^/mL in RPMI containing 5 % heat-inactivated human AB serum (ICN Biomedicals; Aurora, OH) supplemented with 100 ng/mL of granulocyte macrophage colony-stimulating factor (kindly provided by Kirin Pharma, Tokyo, Japan) and 50 ng/mL of interleukin-4 (kindly provided by Ono Pharmaceuticals, Osaka, Japan) at 37 °C in 5 % CO~2~ for 5 days. Cells were confirmed to be CD11c-positive myeloid immature dendritic cells (DC).

Interferon-γ (IFNγ) ELISPOT assay with myeloid DC and CD4-positive T-cells {#Sec10}
--------------------------------------------------------------------------

The immature DC cultures were exposed to recombinant HBsAg and HBcAg (1 μg/mL each) for 1 day. To mature the DCs, 1 ng/mL of lipopolysaccharide (LPS) (Sigma, St. Louis, MO) was added to the culture 1 day after HBV protein addition. On the same day, mouse anti-human interferon-γ antibody (MABTECH, Sweden) was diluted to 5 μg/mL with ELISPOT buffer (0.159 % Na~2~CO~3~, 0.293 % NaHCO~3~) and coated overnight at 4 °C onto 96-well filtration plates (Millipore, Billerica, MA) at 100 μL per well. The coated plate was washed with phosphate-buffered saline (PBS) and blocked with 10 % fetal calf serum in RPMI1640 medium for 1--2 h. Myeloid DCs were counted and seeded at 5 × 10^3^/well. Cryopreserved T4 cells were thawed, counted, and seeded at 2 × 10^5^/well. On the next day, the plate was washed six times with PBS. Wells were coated with rabbit anti-interferon-γ serum (diluted to 1/800 in PBS), and the plate was incubated at 37 °C for 2 h. The plate was washed six times with PBS and coated with goat anti-rabbit immunoglobulin G-alkaline phosphatase (IgG-AP; Southern Biotech, Birmingham, AL) diluted to 1/2000 with PBS. After a 1 h incubation at 37 °C, the plate was washed six times with water and spots were developed using 5-bromo-4-chloro-3-indolyl phosphate *p*-toluidine salt and nitroblue tetrazolium chloride (BCIP/NBT) as a substrate. Spot development was stopped after 10 min by washing with distilled water. The spots were viewed and counted under a microscope.

Statistical analysis {#Sec11}
--------------------

Statistical comparisons were performed using JMP version 9 (SAS Institute, Cary, NC, USA). The Wilcoxon rank-sum test was used to compare the continuous data and the Chi-square test was used to compare categorical data. For multivariate analysis, logistic regression analysis was used. The Steel--Dwass test was used for multiple group analysis. A *p* value of \<0.05 was considered significant.

Results {#Sec12}
=======

The effects of HBV vaccination {#Sec13}
------------------------------

None of the patients in the ALF-OLT group showed reactivation of the virus. One patient of the LC-OLT group showed transient positive responses for HBsAg and HBV DNA, however, these became negative again with frequent HBIg administration. At the final observation point, no patients showed HBsAg or HBV DNA-positive response. All five ALF-OLT patients had good responses to vaccination (Table [3](#Tab3){ref-type="table"}). A median of four (range 2.5--5) vaccinations were sufficient to induce a good response. In contrast, LC-OLT patients were less responsive, with only nine of 22 displaying a good response. Additionally, these nine good responders required a median of 19 (range 11.5--30) vaccinations before these patients could be weaned from HBIg administration (Fig. [1](#Fig1){ref-type="fig"}).Table 3Results of HBV vaccination*N*ALFLC522Response to vaccination (good/poor responders)5/09/13Number of vaccinations require before ceasing HBIg treatment4 (2.5--5)19 (11.5--30)*HBIg* Hepatitis B immunoglobulinFig. 1Individual patients' timecourse of anti-HBs antibody titer after vaccine administration. The timecourse of the anti-HBs antibody titer after the first vaccine administration is shown. The *arrowhead* indicates a vaccine administration point, and the *square head* indicates an HBIg administration point. **a** Patients who received orthotopic liver transplantation (OLT) due to hepatitis B-related acute liver failure (ALF-OLT). All patients had a good response to vaccination. **b** Patients who received OLT due to liver cirrhosis with a good response to vaccination (LC-OLT good). **c** LC-OLT patients with a poor response to vaccination (LC-OLT poor)

Vaccine safety {#Sec14}
--------------

None of the patients showed any adverse reactions as judged by their general condition, or by laboratory examination. One patient reported itchiness after injection of the eighth vaccination dose, although the symptom subsequently stopped.

The characteristics of vaccine responsiveness in LC-OLT patients {#Sec15}
----------------------------------------------------------------

To determine the characteristics for defining a good response in LC-OLT patients, clinical data from recipients and donors were investigated (Table [4](#Tab4){ref-type="table"}). The background data of the recipients, including HBV-DNA levels, HBeAg positive reactions, HBsAg levels at the time of OLT, and the anti-HBs antibody titer at the time of the initial vaccination did not differ between the good and poor responder groups (Table [5](#Tab5){ref-type="table"}). However, the donor-related factors did differ. Notably, the good responders' donors were relatively high in age (*p* = 0.019) and not blood relatives of the recipients (*p* \< 0.001). These donors (to good responders) showed high anti-HBs antibody titers at the time of OLT (*p* = 0.038). Since all of the patients in this study received LDLT, non-blood-related donors all corresponded to spouses of the OLT recipients. Multivariate logistic regression analysis was carried out with the following variables: donor age at OLT ≥47, non-blood-related donor, donor anti-HBs antibody titer \>100 mIU/mL (Table [6](#Tab6){ref-type="table"}). A status of non-blood-related donor was identified as a significant independent predictor of a good response to vaccination. Since the donor anti-HBs antibody was one of the factors associated with a good response, we asked whether the donors had received vaccination, and found that none of them had ever received an HBV vaccine. As shown in Table [4](#Tab4){ref-type="table"}, none of the donors showed the anti-HBc antibody-negative, anti-HBs antibody-positive condition which indicates vaccine-induced seropositivity to the HBs antigen.Table 4LC patient characteristicsCharacteristics of recipientsCharacteristics of donorsPatient's numberResponse to vaccineAge (year) at OLTSexHBsAg (mIU/mL) at OLTHBsAb at OLTHBeAg/HBeAb at OLTHBV DNA (logcopies/mL) at OLTMELD at OLTHCC at OLTTime of vaccinatio n (months post-OLT)HBsAb (mIU/mL) at vaccineNA at vaccineAge at OLTSexBlood relationABO compatibilityHBcAbHBsAbHBsAb (mIU/mL)1Good56M100--−/+\<3.717+5149LAM52F--Compatible----\<0.12Good48M\>2000--+/+3.520+2423LAM46F--Compatible++1343Good44M100--+/−\<3.712--551LAM48F+Identical++1894Good50M\>2000--+/−3.49+4225LAM + ADV48F--Compatible++6275Good54M\>2000--−/+3.815--4043LAM + ADV48F--Compatible----\<0.16Good57M\>2000--−/+2.715+4518LAM53F--Identical----\<0.17Good48M642--+/−4.817--297LAM44F--Compatible++1798Good47F\>2000--+/−4.512--196LAM50M--Compatible++10009Good55M\>2000--+/−6.121+496LAM + ADV48M+Identical++13310Poor52M\>2000--+/−5.38+254LAM21M+Compatible++100011Poor62M\>2000--−/+\<2.68+1317LAM + ADV36M+Identical----\<0.112Poor39M\>2000--+/−\<2.67--30169LAM35F+Identical----\<0.113Poor49M100--−/+4.021+10732LAM22F+Identical----\<0.114Poor26M100--+/−5.520+7530LAM53M+Identical++39715Poor54F100--+/−4.622+551LAM28M+Identical----\<0.116Poor50M160--−/+2.718+386LAM25M+Compatible+--\<0.117Poor44M\>2000--−/+\<2.615--3214LAM47F+Compatible----\<0.118Poor55F\>2000--+/−2.810+1910LAM + ADV51F+Identical++4419Poor54M\>2000--−/−\<2.68+1847ETV49F--Compatible++100020Poor63M1740--−/+\<2.612--1742LAM + ADV36M+Identical----0.221Poor58M35--−/+\<2.616--1619ETV33F+Identical----0.322Poor61M\>2000--−/+2.915+685LAM26M+Identical----\<0.1*NA* nucleos(t)ide analogue, *LAM* lamivudine, *ADV* adefovir dipivoxyl, *ETV* entecavir, *HBcAb* anti-HBc antibody, *HBsAb* anti-HBs antibodyTable 5Patient characteristics according to vaccine responsiveness in LC (univariate analysis)*N*Good respondersPoor responders*p* value913Recipient related factors Age at OLT50 (47--55)54 (46--59)0.546 Sex (male)8 (88 %)11 (84 %)0.774 Time of vaccination (months after OLT)42 (26--50)30 (17--61)0.442 HBsAg at OLT (≥1500 IU/l)6 (66 %)8 (61 %)0.805 HBeAg positive at OLT6 (66 %)5 (38 %)0.190 HBV DNA at OLT (≥3.7 logcopies/mL)4 (44 %)4 (30 %)0.513 MELD at OLT15 \[[@CR12]--[@CR18]\]15 \[[@CR8]--[@CR19]\]0.480 Child-Pugh score at OLT10 \[[@CR8]--[@CR10]\]9 \[[@CR6]--[@CR11]\]0.845 HCC at OLT (+)6 (66 %)9 (69 %)0.899 Anti-HBs antibody titer at the start of vaccination18.6 (6.4--34.6)17.4 (5.9--37.1)0.920 Nucleos(t)ide analogue (LAM/LAM + ADV/ETV)6/3/08/3/20.312 Tacrolimus/cyclosporinA6/311/1\#0.148 Tacrolimus level (ng/mL)4.7 (3.0--5.6)3.8 (2.9--5.8)0.744Donor-related factors Age at OLT48 (47--51)33 (25--48)0.019\* Sex (M)2 (22 %)7 (53 %)0.138 ABO (identical)3 (33 %)9 (69 %)0.093 Blood relation (no)7 (77 %)1 (7 %)\<0.001\* Anti-HBs antibody titer (\>100)6 (66 %)3 (23 %)0.038\* Anti-HBc antibody (+)6 (66 %)5 (38 %)0.190 Anti-HBc(+)/anti-HBs(+)6 (66 %)4 (30 %)0.093 Anti-HBc(+)/anti-HBs(−)0 (0 %)1 (7 %)0.297 Anti-HBc(−)/anti-HBs(+)0 (0 %)0 (0 %)--*MELD* Model for End-stage Liver Disease, *HCC* hepatocellular carcinoma, *LAM* lamivudine, *ADV* adefovir dipivoxyl, *ETV* entecavir^\#^One patient received no calcineurin inhibitorTable 6Multiple logistic analysis of factors associated with good responses to HBV vaccine in LC*N*Odds ratio95 % CI*p* valueAge at OLT (\>47)5.40.300--214.0000.244Blood relation (no)29.42.551--984.1100.005\*Anti-HBs antibody titer (\>100)5.00.343--149.9470.233*Note*: Variables significant at *p* \< 0.05

HBV antigen-specific immune responses {#Sec16}
-------------------------------------

To determine the effectiveness of vaccine-induced cellular immune responses in post-OLT patients, we used the IFN-γ ELISPOT assay. First of all, we analyzed the clinical characteristics of those patients showing strong HBsAg-specific T cell immune responses when compared with those of non-transplanted patients, and vaccine-induced anti-HBs antibody-positive, healthy volunteers (Fig. [2](#Fig2){ref-type="fig"}). The patients with stronger HBsAg-specific CD4 T cell IFN-γ responses (equal or more than the median; 7 spots) showed lower levels of HBV DNA, lower HBsAg, higher anti-HBs antibody titer, and higher HBcAg-specific immune responses. The HBsAg and HBcAg-specific CD4 T cell immune response under different clinical conditions is shown (Fig. [3](#Fig3){ref-type="fig"}). Volunteer controls who were positive for anti-HBs antibodies (as a result of previous vaccine administration) showed numerous HBsAg-specific IFNγ spots. Spot numbers were reduced in control chronic hepatitis B patients, but remained high (against both HBsAg and HBcAg) in acute resolved hepatitis B patients. The ALF-OLT and LC-OLT good responders had relatively higher HBsAg-specific T-cell immune responses than LC-OLT poor responders. The LC-OLT patients with successful vaccine-induced humoral immune responses also showed higher cellular immune responses than control chronic hepatitis B patients. The LC-OLT patients with poor vaccine responses also had low cellular responses, similar to those seen in chronic hepatitis B patients.Fig. 2The clinical characteristics of the non-OLT patients with strong HBsAg-specific T cell interferon-γ response. The clinical characteristics of the non-OLT patients showing strong HBsAg-specific T cell immune responses by enzyme-linked immunospot (ELISPOT) assay are shown. Those patients with stronger HBsAg-specific CD4 T cell IFN-γ response (equal or more than the median; 7 spots) showed lower HBV DNA, lower HBsAg, higher anti-HBs antibody titer, and higher HBcAg-specific immune responsesFig. 3Cellular immune responses against HBsAg including OLT patients. The number of spots due to interferon-γ response in the ELISPOT assay for HBsAg (*upper figure*) and HBcAg (*lower figure*) is shown. *1* Healthy vaccine: healthy controls who were positive for anti-HBs antibodies with HBV vaccine (*n* = 11). *2* Chronic hepatitis: chronic hepatitis B patients (*n* = 10). *3* Self-limited: self-limited acute hepatitis B patients who showed serum anti-HBs antibody-positive/HBcAb-positive with no HBsAg or HBV-DNA (*n* = 5). *4* ALF-OLT: post-OLT acute liver failure patients (*n* = 4). *5* LC-OLT good: post-OLT liver cirrhosis patients who showed good response to vaccine (*n* = 8). *6* LC-OLT poor: post-OLT liver cirrhosis patients who showed poor response to vaccine (*n* = 7). Values are plotted as median (range)

Discussion {#Sec17}
==========

In this study we found that HBV vaccination was effective in OLT patients whose donors were relatively high in age, marital (non-blood-related), with high-titer anti-HBs antibodies. The multivariate analysis revealed that a marital (non-blood-related) donor was the only factor that associated strongly with a good response to vaccine. Among these OLT recipients, a good response to vaccination included effective responses in both the humoral and cellular arms of the immune system.

Controlling HBV reactivation after OLT is critical. In the absence of prophylaxis, hepatitis B recurs very frequently and results in early graft failure. The prophylaxis protocols have progressed from HBIg immunoprophylaxis in the early 1990s, to lamivudine in the late 1990s, to the more recent application of HBIg combined with nucleos(t)ide analogues. In 1991, Muller et al. \[[@CR17]\] reported the first use of long-term HBIg immunoprophylaxis, reducing the HBV recurrence rate to 25 % after 6 months of OLT and 18 % after 12 months. A multicenter study revealed that the three-year risk of HBV recurrence was 75 ± 6 % without HBIg, 74 ± 5 % with short-term (2-month) HBIg, and 36 ± 4 % with long-term (\>6-month) HBIg treatment \[[@CR18]\]. Patients who were positive for HBeAg or HBV-DNA displayed the greatest risk of recurrence (83 %); patients with acute fulminant liver failure showed the lowest risk (16 %).

In 1996, Grellier et al. \[[@CR19]\] reported a trial of LAM as a prophylactic treatment, achieving 18 % recurrence of HBV at 6 months after OLT. However, the long-term recurrence rate at 3 years after OLT progressed to 41 %, indicating that LAM monotherapy is not recommendable for post-transplantation prophylaxis.

Although monotherapy with HBIg or LAM resulted in a high rate of recurrence, a combination of these agents has been administered with reasonable success. In 1998, Markowitz et al. \[[@CR20]\] reported no recurrences after 1 year of combination therapy. Since HBIg is very expensive, several reports have described modified combination therapies. We previously have shown that long-term LAM with short-term, high-dose HBIg followed by low-dose HBIg (sufficient to maintain an anti-HBs antibody titer of \>10 mIU/mL) is cost-effective and powerful enough to control HBV recurrence after LDLT \[[@CR13]\]. With this cost-saving method, no clinical evidence of HBV recurrence has been seen.

In 2000, Sanchez-Fueyo et al. \[[@CR21]\] reported an 82 % response to HBV vaccination after OLT. These researchers used three cycles of double-dose recombinant HBsAg vaccine for immunization over 6 months, with a target antibody titer of \>10 mIU/mL. The cohort included six acute infected patients and 11 chronic carriers. However, recent reports show that chronic HBV carrier recipients did not respond well, with response rates ranging from 7.7 to 12.5 % \[[@CR22], [@CR23]\]. Acute HBV-infected patients who underwent OLT were often positive for the anti-HBs antibody even before OLT, with strong immune responses. Such patients might be expected to respond well to vaccination, since these individuals (unlike chronic carriers) have not developed a tolerance to HBV. In our patients, five acute infected patients showed good responses to vaccination, responding after a median of only four vaccinations. These results indicate that while acute HBV-infected patients are good candidates for HBV vaccination post-OLT; chronic HBV carriers are poorer candidates for this protocol. However, as some HBV carriers did respond to vaccination; further studies should be performed to clarify the differences between the good and poor responders.

Several reports have identified the differences between good responders and poor responders in non-HBV-infected patients who received HBcAb-positive donor livers. Lacking previous HBV exposure, these recipients should not have developed tolerance to the virus and so should have been good responders. Of these, good responses were seen in pediatric cases where the recipients had higher anti-HBs antibody titers at the time of OLT and lower tacrolimus levels at the time of vaccination \[[@CR24]\]. The present study revealed that repeated vaccine administration resulted in successful immunization in 40 % of the LC-OLT recipients. For these recipients, the strength of the response did not correlate with recipient characteristics, not even with age, one of the most important factors for successful immunization \[[@CR25]\]. In contrast, the characteristics of the donor were important. The good responders' donors were relatively high in age, non-blood-related and had high anti-HBs antibody titers before donation. Note that, in our trial, the term "non-blood-related donor" indicates the spouse of the recipient, since deceased donor liver transplantation is not widely accepted in Japan \[[@CR26]\]. The donors with high-titer anti-HBs antibody probably were infected with HBV by the recipients after their marriage, resulting in the anti-HBs antibody boost. These donors' immune systems should not have developed tolerance to the virus. This elevated immunity might be the reason why our patients had relatively better outcomes following vaccination than those of previous reports \[[@CR27]\]. Adoptive immune transfer of HBV-specific immune response could be possible \[[@CR28]\]. For successful transfer of immune memory to the recipients, the anti-HBs antibody titer of the donors should be high, and vaccine-induced anti-HBs antibody might be less effective than antibodies produced in a previous self-limited infection. Luo et al. \[[@CR29]\] have shown that a particularly high anti-HBs antibody titer (\>1000 IU/L) in the donor is essential for adoptive immune transfer. The results of the present study suggest that HBV vaccination of non-blood-related living donor candidates having a lower anti-HBs antibody titer (\<100 mIU/mL) might facilitate improved vaccine response post-OLT in LC recipients.

The present study of HBV vaccine efficacy in ALF-OLT and LC-OLT patients revealed that the vaccine response depended on the immune tolerance to the virus in both recipients and donors. The liver is the biggest immune organ in the abdomen and so can play a critical role in immune responses. Multiple populations of non-hematopoietic liver cells, including sinusoidal endothelial cells, stellate cells located in the subendothelial space, and liver parenchymal cells, take on the roles of antigen-presenting cells \[[@CR30]\]. The viral-specific immune competence of the grafted liver might overcome the general immunotolerance to the virus in chronic HBV carriers.

In conclusion, patients who received OLT due to acute infection of HBV were good candidates for HBV vaccination. The chronic HBV carrier recipients who received livers from donors who were non-blood-related (i.e, the recipient's spouse) and who harbored high anti-HBs antibody titers were the best candidates for HBV vaccine administration. Vaccine-induced, HBV-specific immune responses were strong enough to induce not only humoral but also cellular responses in vitro.
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